Multicenter Randomized Open-Label Phase II Clinical Study Comparing Outcomes of NK105 and Paclitaxel in Advanced or Recurrent Breast Cancer.
Yoshimasa KosakaToshiaki SaekiToshimi TakanoTomoyuki ArugaToshinari YamashitaNorikazu MasudaYukio KoibuchiAkihiko OsakiJunichiro WatanabeRyu SuzukiPublished in: International journal of nanomedicine (2022)
Weekly NK105 administration was well-tolerated. Efficacy was similar in both groups. The PSN profile was better in the NK105 group.